Skip to content

G&A at other companies

EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
$15.24M+9.9%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$20.01M+22.4%
Staar Surgical logo
Staar SurgicalSTAA
$17.02M-30.4%

Other financials

Income statement

See full
Operating income-$15.4M-108%
Net income-$13.8M-56.6%
EPS (diluted)-$0.69+82.6%

Balance sheet

See full
Cash & equivalents$238.9M+312%
Total debt$1.6M
Total equity$250.1M+463%
Total assets$258.4M

Cash flow

See full
Operating cash flow-$13.5M-65.2%
CapEx$676.0K+312%
Free cash flow-$14.2M-70.0%

Valuation

See full
Market cap$744.23M-23.4%
Enterprise value$506.93M

Returns & leverage

See full
Return on equity-34.3%
Debt / equity
Current ratio38×

Where this comes from

Reported directly by Schering-Plough in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Schering-Plough’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Schering-Plough's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Schering-Plough's G&A?
Schering-Plough (SGP) reported G&A of $6.87M in Q1 2026.
How has Schering-Plough's G&A changed year-over-year?
Schering-Plough's G&A increased by 400.9% year-over-year, from $1.37M to $6.87M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.